Fits and Starts: Trial Results from the CTAD Conference
In Barcelona, data ran the gamut from a few hopeful little hints on new treatments to mixed signals on familiar players, and failed drugs thrown on the scrap heap.
ALL NEWS
5723 RESULTS
Sort By:
- Most Recent
- Most Commented
Doubling Down on Sequencing Serves up More Alzheimer’s Genes
New genetic variants emerged by harmonizing whole-exome-sequencing data across continents, and by using imputation to plumb the depths of existing GWAS. One variant encodes a microglial phospholipid transporter.
IDEAS Finds Small Drop in Hospitalizations, Missing Goal
A slight drop in hospital admissions after amyloid PET, especially in people with positive scans, fell well short of the prespecified endpoint. Still, IDEAS is broadening into a research platform, and IDEAS 2 will add racial diversity.
Potential Parkinson’s Treatments Target α-Synuclein, Cell Replacement
Two drugs that boost α-synuclein clearance have passed Phase 1 safety benchmarks, and a stem cell strategy is poised to enter trials, reported scientists at SfN 2015.
Lancet Commission’s Dementia Hit List Adds Alcohol, Pollution, TBI
In updating their broad evaluation of the risk literature, the commission blamed three more modifiable factors for causing 6 percent of all dementia, concluding that 40 percent of cases can be prevented.
Heart Health Is Brain Health, and It Starts in Your 20s
New research pushes back the age at which dementia risk from cardiovascular and metabolic factors begins. Should protective lifestyle interventions start in youth?
Alzheimer's Association International Conference 2020 (Virtual Meeting Only)
Plasma p-Tau217 Set to Transform Alzheimer’s Diagnostics Could Common Vaccines Protect Against Alzheimer’s Disease? Doubling Down on Sequencing Serves up More Alzheimer’s Genes IDEAS Finds Small Drop in Hospitalizations, Missing Goal Lancet Commission’s ...
Confused About the DIAN-TU Trial Data? Experts Discuss
The AAT-AD/PD conference hosted a virtual conversation about what the trial’s disappointing cognitive and tantalizing biomarker data might mean. Hidden between thank you’s and pledges to stay committed were substantive points of debate and context.
Umibecestat-Driven Cognitive Decline Is Reversible
Subtle memory deficits resolved after volunteers stopped taking the Novartis BACE inhibitor.
At AAIC, Hints of Target Engagement for Some Drug Candidates
Early data suggest that CT1812 and AL001 shift biomarker levels in Alzheimer’s disease and frontotemporal dementia, respectively. BI 425809 fails to improve cognition.
NEALS: Collaboration for a Cure to ALS
In the field of amyotrophic lateral sclerosis (ALS), the Northeast ALS Consortium (NEALS) is the hands-down largest and hardest-working township in North America...
Astrocytes and Exosomes Implicated in Protein Propagation
Researchers at SfN 2016 painted a more detailed picture of how misfolded proteins may proliferate, as one cell spreads these “hot potatoes” to the next.
FDA Accepts Aducanumab Application for Priority Review
The FDA will decide whether to approve the antibody as a treatment for Alzheimer’s disease on or before March 7, 2021.
Global Genetics Symposium Starts Today
Three weeks of on-demand seminars to culminate in live Q&A.
First Round of FTD Therapeutics Fell Short, But Many More Are Up and Running
Researchers reported negative findings from three trials at ICFTD 2016.
Current Filters
- Date Range : All x